Vaxcyte, Inc.
NASDAQ:PCVXBiotechnology
+$1.94 today
- Market cap
- $9.26B
- Beta
- 1.24
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$6.78
Volume 1.13M
Average 1.44M
PCVX Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Vaxcyte, Inc.NASDAQ: PCVX
Investing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Investing cash flow turns negative
Q2 FY2026 investing cash flow was -$85.69M, compared with $77.74M a year earlier. Trailing-twelve-month investing cash flow was -$82.81M. Over 3 fiscal years it compounded at +80.3% a year.
Context
- Investing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly investing cash flow holds near -$85.69M or moves back toward the trailing-twelve-month quarterly average of -$20.7M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 437.35M USD
- Year-over-year change
- +121.8%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 437.35M | +121.8% |
| FY2024 | 2024-12-31 | (2.01B) | -159.4% |
| FY2023 | 2023-12-31 | (773.31M) | -1136.8% |
| FY2022 | 2022-12-31 | 74.59M | +135.1% |
| FY2021 | 2021-12-31 | (212.31M) | — |
Investing Cash Flow vs competitors
How PCVX compares with its peers on the latest reported figures
- Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -93.5% is the 7th highest of 9, against a peer median of -77.5%.
- Over three fiscal years its annual growth of +80.3% compares with a peer median of -55.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | £6.86B GBP | +89.5% | -19.3% | 20.7% | |
| LTM Jun 2026 | $5.69B USD | -260.4% | -55.9% | 8.9% | |
| LTM Sep 2026 | $1.51B USD | -203.8% | — | 59.8% | |
| LTM Mar 2026 | $195.39M USD | -67.3% | — | 298.3% | |
| LTM Sep 2026 | $103.59M USD | -43.6% | — | 56.7% | |
| LTM Jun 2026 | $82.81M USD | -93.5% | +80.3% | — | |
| LTM Mar 2026 | $33.31M USD | -87.7% | -5.6% | 5.6% | |
| LTM Mar 2026 | €5.77M EUR | -46.4% | -61.1% | 3.7% | |
| LTM Mar 2026 | $59.66K USD | -89.1% | -69.0% | 0.1% | |
| Peer median (excluding PCVX) | — | -77.5% | -55.9% | 14.8% | |
Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (100.08M) | (223.49M) | (402.27M) | (463.93M) | (766.63M) |
| Depreciation & Amortization | 3.46M | 9.45M | 10.17M | 15.85M | 24.86M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.73M | 23.65M | 48.76M | 84.82M | 138.85M |
| Change in Working Capital | (37.01M) | 12.74M | 81.32M | (54.9M) | (3.45M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (12.47M) | 2.9M | 11.23M | 34.58M | 19.91M |
| Other Working Capital | (24.54M) | 9.84M | 70.1M | (89.48M) | (23.36M) |
| Other Non-Cash Items | 1.5M | 7.05M | (34.78M) | (34.47M) | (49.2M) |
| Operating Cash Flow | (121.39M) | (170.6M) | (296.79M) | (452.63M) | (655.58M) |
| Capital Expenditures | (6.56M) | (5.84M) | (67.88M) | (22.43M) | (13.71M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (336.34M) | (102.75M) | (1.33B) | (3.09B) | (1.21B) |
| Sales of Investments | 130.56M | 183.17M | 624.46M | 1.2B | 1.71B |
| Other Investing Activities | 26K | 0 | 0 | (96.73M) | (43.26M) |
| Investing Cash Flow | (212.31M) | 74.59M | (773.31M) | (2.01B) | 437.35M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 13.9M | 856.48M | 636.04M | 2.44B | 13.01M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.9M | 5.07M | 3.77M | 12.85M | (10.99M) |
| Financing Cash Flow | 17.8M | 861.55M | 639.81M | 2.45B | 2.01M |
| Effect of Forex Changes | (439K) | 137K | (6.69M) | 426K | 2.44M |
| Net Change in Cash | (316.34M) | 765.67M | (436.97M) | (9.36M) | (213.77M) |
| Free Cash Flow | (127.95M) | (176.44M) | (364.67M) | (475.05M) | (669.29M) |
Vaxcyte, Inc.
NASDAQ:PCVX
Intrinsic Alpha fair value
Locked
Current Price
$58.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.